AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31797710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil administration 2 hours prior to radiocontrast administration and the subsequent day
Number of subjects: 0
Study 31797710 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl-L-cysteine treatment 1 day before and on the day of radiocontrast administration
Number of subjects: 0
Study 29334403 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft from tuberosity area (TG)
Number of subjects: 32
Study 29334403 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft from lateral palate (CG)
Number of subjects: 32
Study 26146039 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g cooked African leafy vegetable (ALV) dish and school meal starch, five times per week for three months (n 86)
Number of subjects: 167
Study 26146039 — intervention group
Group type: COMPARATOR
Intervention: Normal school meal (n 81)
Number of subjects: 167
Study 25060955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs at baseline
Number of subjects: 90
Study 25060955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs at 3-month follow-up
Number of subjects: 90
Study 25060955 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of complaints and baseline disability
Number of subjects: 90
Study 22864376 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard protocol
Number of subjects: 10
Study 22864376 — intervention group
Group type: COMPARATOR
Intervention: Minimized prescan adjustment protocol
Number of subjects: 10
Study 20396716 — intervention group
Group type: EXPERIMENTAL
Intervention: Artrofoon
Number of subjects: 0
Study 17976261 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) preparation of racemic ibuprofen
Number of subjects: 12
Study 17976261 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) preparation of racemic ibuprofen
Number of subjects: 12
Study 16390770 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day 17beta-estradiol combined with 5 or 10 mg/day dydrogesterone
Number of subjects: 579
Study 16390770 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day 17beta-estradiol combined with 10 or 20 mg/day dydrogesterone
Number of subjects: 579
Study 16390770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study 12581544 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg/d to 400 mg/d)
Number of subjects: 2327
Study 9467474 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin
Number of subjects: 205
Study 9467474 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 205
Study 9467474 — intervention group
Group type: EXPERIMENTAL
Intervention: TUMT (transurethral microwave thermotherapy, 52 degrees C for 60 min, microwave energy 200 kJ)
Number of subjects: 205
Study 9467474 — intervention group
Group type: COMPARATOR
Intervention: Boyarsky index
Number of subjects: 205
Study 7533824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (100 mg/m2/week or 80 mg/m2/week for prior radiation therapy patients)
Number of subjects: 162
Study 7533824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 162
Study 2668524 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 94
Study 2668524 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 94
Study 824875 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term treatment with Partusisten and Isoptin
Number of subjects: 50
Study 824875 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term treatment with Partusisten only
Number of subjects: 50
Study 824875 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term treatment with Partusisten and Isoptin
Number of subjects: 50
Study 824875 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 50
Study 824875 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term treatment with Partusisten only
Number of subjects: 50
Study 31527700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis plus treatment-as-usual (EG, n=8)
Number of subjects: 20
Study 31527700 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual only (CG, n=10)
Number of subjects: 20
Study 28322912 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal prenatal cortisol sampled on waking
Number of subjects: 216
Study 28322912 — intervention group
Group type: COMPARATOR
Intervention: 30-min post-waking cortisol measure
Number of subjects: 216
Study 28322912 — intervention group
Group type: COMPARATOR
Intervention: Evening cortisol measure
Number of subjects: 216
Study 26002818 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive ICD programming
Number of subjects: 543
Study 26002818 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICD programming
Number of subjects: 543
Study 26002818 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive ICD programming with dual-chamber detection devices
Number of subjects: 543
Study 23683667 — intervention group
Group type: COMPARATOR
Intervention: Profluss® for 6 months (group I)
Number of subjects: 168
Study 23683667 — intervention group
Group type: COMPARATOR
Intervention: Profluss® + a-blockers for 3 months (group II)
Number of subjects: 168
Study 21896650 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 200 μg/d as selenomethionine
Number of subjects: 423
Study 21896650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 19193252 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program in dementia care (three-month duration)
Number of subjects: 96
Study 19193252 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group (RG)
Number of subjects: 96
Study 19193252 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (CG)
Number of subjects: 96
Study 17096032 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic prophylaxis (exact dosage and duration not specified)
Number of subjects: 0
Study 17096032 — intervention group
Group type: COMPARATOR
Intervention: First and second-generation cephalosporins (exact dosage and duration not specified)
Number of subjects: 0
Study 15112940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention approaches for hazardous drinking
Number of subjects: 0
Study 15112940 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational feedback on the college campus
Number of subjects: 0
Study 15112940 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized alcohol harm reduction feedback intervention
Number of subjects: 0
Study 15112940 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions
Number of subjects: 0
Study 10899481 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol (EE2) plus 75 microg gestodene (GES)
Number of subjects: 0
Study 10899481 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol (EE2) plus 75 microg gestodene (GES)
Number of subjects: 0
Study 10899481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contraception)
Number of subjects: 0
Study 9285885 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc absorption from a standard breakfast labelled with 3 mg 67Zn.
Number of subjects: 20
Study 9285885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.5 mg 70Zn (as citrate).
Number of subjects: 20
Study 9285885 — intervention group
Group type: COMPARATOR
Intervention: Urinary zinc excretion measurement.
Number of subjects: 20
Study 8362773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10 to 40 mg)
Number of subjects: 19
Study 8362773 — intervention group
Group type: COMPARATOR
Intervention: Isradipine (5 to 20 mg)
Number of subjects: 19
Study 3706857 — intervention group
Group type: EXPERIMENTAL
Intervention: External cardiac compression (ECC) performed at the lower one-third of the sternum 1.5 to 2 cm above the tip of the xiphoid
Number of subjects: 97
Study 3706857 — intervention group
Group type: COMPARATOR
Intervention: External cardiac compression (ECC) performed at the midsternum at the level of the victim's nipples
Number of subjects: 97
Study 30741868 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 vs. 3 small-sided games (SSGs) for 3 × 2 minutes with 1 minute passive recovery
Number of subjects: 12
Study 30741868 — intervention group
Group type: COMPARATOR
Intervention: Traditional warm-up strategies (specific handball shooting drills)
Number of subjects: 12
Study 28965176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein added to chocolate beverage (24g)
Number of subjects: 20
Study 28965176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice protein added to chocolate beverage (24g)
Number of subjects: 20
Study 28965176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat protein added to chocolate beverage (24g)
Number of subjects: 20
Study 28965176 — intervention group
Group type: COMPARATOR
Intervention: Chocolate beverage alone (50g carbohydrate)
Number of subjects: 20
Study 26676059 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of supervised moderate intensity exercise training
Number of subjects: 21
Study 24113628 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 334
Study 24113628 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 334
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements
Number of subjects: 4221
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 4221
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific anti-osteoporotic drugs
Number of subjects: 4221
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Any osteoporosis medication
Number of subjects: 4221
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific anti-osteoporotic drug
Number of subjects: 4221
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 4221
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis medication in women with major osteoporotic fracture
Number of subjects: 4221
Study 24114665 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D use among specific osteoporosis drug users
Number of subjects: 4221
Study 20934601 — intervention group
Group type: EXPERIMENTAL
Intervention: Passion fruit peel extract (PFP), 150 mg daily for 2 months
Number of subjects: 33
Study 20934601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18589444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus size measurement in children not vaccinated with Bacille Calmette‐Guérin (BCG) or vaccinated with BCG in the preceding 4 weeks
Number of subjects: 923
Study 18589444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus size measurement in children who had malaria or were treated with chloroquine or Quinimax in the previous week
Number of subjects: 923
Study 18589444 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymus size measurement controlling for background factors associated with thymus size and mortality
Number of subjects: 923
Study 15800559 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (55% carbohydrate, 15% protein, 30% fat)
Number of subjects: 12
Study 15800559 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (40% carbohydrate, 30% protein, 30% fat)
Number of subjects: 12
Study 12803510 — intervention group
Group type: COMPARATOR
Intervention: lisinopril 10 mg/day
Number of subjects: 50
Study 12803510 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril 10 mg/day and pentoxifylline 600 mg/day for nine months
Number of subjects: 50
Study 10327508 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation-oriented approach (n = 30)
Number of subjects: 710
Study 10327508 — intervention group
Group type: COMPARATOR
Intervention: Usual claim-based practice (Control group, n = 30)
Number of subjects: 710
Study 8576508 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (5 days/week for 12 weeks, max 30 minutes/day)
Number of subjects: 41
Study 8576508 — intervention group
Group type: COMPARATOR
Intervention: Social visit control group (weekly visits for 30 minutes)
Number of subjects: 41
Study 8576508 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (22 weeks)
Number of subjects: 41
Study 8576508 — intervention group
Group type: COMPARATOR
Intervention: Social visit control group (22 weeks)
Number of subjects: 41
Study 1670062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialytic ultrafiltration
Number of subjects: 8
Study 1670062 — intervention group
Group type: COMPARATOR
Intervention: Large-volume paracentesis
Number of subjects: 8
Study 7056105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil therapy in chronic AF with rapid rate at rest
Number of subjects: 13
Study 7056105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil therapy in chronic AF with accelerated rate during exercise
Number of subjects: 13
Study 7056105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil therapy in paroxysmal AF
Number of subjects: 13
Study 31088552 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried marital status
Number of subjects: 413
Study 31088552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid upper arm circumference (MUAC) < 11 cm
Number of subjects: 413
Study 28806366 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling DVD intervention
Number of subjects: 619
Study 28806366 — intervention group
Group type: COMPARATOR
Intervention: Didactic comparison DVD
Number of subjects: 619
Study 26380238 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive pudendal nerve block with 0.3 cc/kg bupivacaine 0.25%
Number of subjects: 60
Study 26380238 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study 26380238 — intervention group
Group type: COMPARATOR
Intervention: Both groups (sitting position)
Number of subjects: 60
Study 25142999 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV-r) 400-100 mg twice/day for 29.5 days followed by P. ginseng 500 mg twice/day for 2 weeks
Number of subjects: 12
Study 25142999 — intervention group
Group type: EXPERIMENTAL
Intervention: P. ginseng 500 mg twice/day for 2 weeks
Number of subjects: 12
Study 21070230 — intervention group
Group type: EXPERIMENTAL
Intervention: telcagepant 280/300 mg
Number of subjects: 1068
Study 21070230 — intervention group
Group type: COMPARATOR
Intervention: rizatriptan 10 mg
Number of subjects: 1068
Study 19524389 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, personally tailored counseling sessions based on lung functioning, CO exposure, and smoking-related health conditions.
Number of subjects: 536
Study 19524389 — intervention group
Group type: COMPARATOR
Intervention: Generic smoking-risk information and personalized counseling about diet, BMI, and physical activity.
Number of subjects: 536
Study 18614724 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid dark chocolate (22 g cocoa powder)
Number of subjects: 45
Study 18614724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free cocoa (22 g cocoa powder)
Number of subjects: 45
Study 18614724 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugared cocoa (22 g cocoa powder)
Number of subjects: 45
Study 18614724 — intervention group
Group type: COMPARATOR
Intervention: Cocoa-free placebo bar (0 g cocoa powder)
Number of subjects: 45
Study 18614724 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g cocoa powder)
Number of subjects: 45
Study 15863986 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 100
Study 15863986 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 100
Study 12051570 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 80 mg/day Ginkgo special extract EGb 761
Number of subjects: 60
Study 12051570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10541424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 375
Study 10541424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 375
Study 10541424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 10541424 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine vs Cetirizine
Number of subjects: 375
Study 7603600 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide injection
Number of subjects: 60
Study 7603600 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 60
Study 7603600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contrast media
Number of subjects: 60
Study 2190933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (one dose)
Number of subjects: 502
Study 2190933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 489772 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily sotalol administration (80 to 320 mg)
Number of subjects: 30
Study 489772 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily sotalol administration (80 to 320 mg)
Number of subjects: 30
Study 30736977 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective use of T-tube during CCS
Number of subjects: 405
Study 30736977 — intervention group
Group type: COMPARATOR
Intervention: No T-tube placement (Control)
Number of subjects: 405
Study 29070637 — intervention group
Group type: EXPERIMENTAL
Intervention: Active photobiomodulation therapy (PBMT)
Number of subjects: 148
Study 29070637 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 148
Study 29070637 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBMT
Number of subjects: 148
Study 26382580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis, BB-12® (1 or 10 billion colony-forming units/d)
Number of subjects: 1248
Study 26382580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1248
Study 23856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleobuvir 100 mg q8h for 5 days
Number of subjects: 73
Study 23856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleobuvir 200 mg q8h for 5 days
Number of subjects: 73
Study 23856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleobuvir 400 mg q8h for 5 days
Number of subjects: 73
Study 23856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleobuvir 800 mg q8h for 5 days
Number of subjects: 73
Study 23856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleobuvir 1200 mg q8h for 5 days
Number of subjects: 73
Study 23856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleobuvir 400 mg q8h for 5 days (for patients with cirrhosis)
Number of subjects: 73
Study 23856779 — intervention group
Group type: EXPERIMENTAL
Intervention: Deleobuvir 600 mg q8h for 5 days (for patients with cirrhosis)
Number of subjects: 73
Study 23856779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21881539 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg ramipril
Number of subjects: 9
Study 21881539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21141020 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-0 chromic catgut
Number of subjects: 50
Study 21141020 — intervention group
Group type: COMPARATOR
Intervention: 4-0 silk
Number of subjects: 50
Study 17372095 — intervention group
Group type: EXPERIMENTAL
Intervention: Duct tape occlusion therapy (moleskin with transparent duct tape)
Number of subjects: 90
Study 17372095 — intervention group
Group type: COMPARATOR
Intervention: Moleskin alone (control group)
Number of subjects: 90
Study 14980943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of IV phenylephrine at 100 microg/min for 3 min, then 100 microg/min as needed
Number of subjects: 50
Study 14980943 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving IV bolus phenylephrine 100 microg after each SAP <80% of baseline
Number of subjects: 50
Study 11686857 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute Risk (AR)
Number of subjects: 457
Study 11686857 — intervention group
Group type: EXPERIMENTAL
Intervention: Number Needed to Treat (NNT)
Number of subjects: 457
Study 9141377 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 3400
Study 8175974 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose human synthetic BNP infusion (4 pmol/kg.min for 1 h)
Number of subjects: 5
Study 8175974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3066519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (three 200 mg tablets/die for 7 days)
Number of subjects: 121
Study 3066519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 3066519 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 121
Study 29717483 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused psychotherapy
Number of subjects: 88
Study 28084155 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS-TLIF
Number of subjects: 106
Study 28084155 — intervention group
Group type: COMPARATOR
Intervention: Conventional TLIF
Number of subjects: 106
Study 26629174 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion with Chinese herbal
Number of subjects: 355
Study 26629174 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 355
Study 23710718 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy (NPT)
Number of subjects: 307
Study 23710718 — intervention group
Group type: COMPARATOR
Intervention: Traditional occlusive dressing method (Control)
Number of subjects: 307
Study 21443557 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) procedure combined with orthodontic button application (CAF+B)
Number of subjects: 41
Study 21443557 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) procedure (Control group)
Number of subjects: 41
Study 18614981 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES) implantation
Number of subjects: 198
Study 16641576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 10 mg
Number of subjects: 53